<a href="https://www.fiercebiotech.com/biotech/analysts-cut-engene-cancer-sales-forecast-after-updated-data-widen-gap-jj" hreflang="en">Analysts cut enGene cancer sales forecast after updated data widen gap to J&J</a>
Analysts have significantly reduced their sales forecast for enGene Therapeutics' bladder cancer candidate, detalimogene voraplasmid, after disappointing phase 2 trial results indicated a lower than expected efficacy compared to competitors like Johnson & Johnson. The peak sales estimate dropped from $1 billion to $350 million, reflecting concerns about the drug's competitiveness and potential market penetration.
The most valuable insight for someone tracking healthtech and biotech is that enGene Therapeutics' bladder cancer candidate, detalimogene voraplasmid, faces significant commercial challenges due to disappointing phase 2 results, resulting in a dramatic reduction of sales forecasts and stock price targets. This underscores the importance of efficacy data in maintaining competitive positioning in the biotech market, especially when competing with established players like Johnson & Johnson.